Investigating Associations Between Medications and Suicide Risk: A Retrospective Analysis from 2004 to 2024 - Summary - MDSpire

Investigating Associations Between Medications and Suicide Risk: A Retrospective Analysis from 2004 to 2024

  • By

  • Zhilan Zhou

  • Junlin Diao

  • Jie Wan

  • Lurong Yu

  • Limei Liu

  • April 29, 2026

  • 0 min

Share

Objective:

To identify specific associations between drugs and suicide-related adverse events (SAEs) using the FAERS database.

Key Findings:
  • 247,657 reports of SAEs involving 193 drugs were collected, highlighting the significant scale of the analysis.
  • Central nervous system medications were most closely associated with SAEs, indicating a critical area for monitoring.
  • SAEs were more likely to occur during the initial stages of medication use, suggesting a need for careful observation during this period.
  • Montelukast, isotretinoin, and sertraline were the top drugs associated with SAEs in individuals under 18, warranting targeted interventions.
  • Hydrocodone/acetaminophen showed a significantly higher ROR in individuals aged 65 and older, indicating increased risk in this demographic.
  • Quetiapine and paracetamol showed positive signals across all age groups, with ROR strength increasing with age, suggesting a need for age-specific monitoring.
Interpretation:

Significant differences in SAEs timing and associated drug classes exist across age groups and genders, indicating a need for targeted drug safety monitoring and tailored clinical guidelines.

Limitations:
  • The study relies on the FAERS database, which may have reporting biases and underreporting issues.
  • The analysis is retrospective and may not capture all relevant data.
Conclusion:

Findings support the need for targeted monitoring of drug safety in high-risk populations and suggest that combining multiple datasets could enhance understanding and risk assessment.

Original Source(s)

Related Content